Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

What's In Store For STMicroelectronics' (STM) Q2 Earnings?

Published 07/22/2019, 08:54 AM
Updated 07/09/2023, 06:31 AM

STMicroelectronics N.V. (NYSE:STM) is slated to report second-quarter 2019 results on Jul 25.

Notably, the company topped the Zacks Consensus Estimate in two of the trailing four quarters, delivering average positive surprise of 1.82%.

In the last reported quarter, STMicroelectronics reported non-GAAP earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a penny.

First-quarter net revenues also decreased 6.7% year over year to $2.1 billion due to weakness in analog, MEMS and sensors group.

For the second quarter, the company expects net revenues to increase approximately 2.4% and gross margin to grow about 38.5% on a sequential basis.

Let’s see how things are shaping up prior to the earnings announcement.

STMicroelectronics N.V. Price and EPS Surprise

Factors to Consider

In the to-be-reported quarter, the company’s well-performing products are likely to have aided its performance across all end-markets served. Moreover, the company’s higher-value products will likely contribute to top-line growth in the quarter.

For the second quarter, STMicroelectronics remains optimistic about strong momentum across industrial, automotive and personal electronics markets, thanks to growing demand for smartphone applications.

The company has been witnessing growing contract wins in areas of braking, body control and engine management. This is expected to help STMicroelectronics to sustain momentum in the automotive market.

In the soon-to-be-reported quarter, the company’s robust microcontrollers, sensors, power, analog and other connectivity products will likely aid the top line in the industrial market.

The increasing usage of electronic applications in cars, especially smart cars and autonomous vehicles, remains a positive for the company’s growth in the automotive market. STMicroelectronics’ expanding design wins for silicon carbide products will likely be a majordriver of top-line growth in this particular market.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Concerns

Weak pricing power pressure on the chip market, especially for the NAND flash memory, and increasing levels of inventory continue to be overhangs.

The ongoing trade tension regarding tariffs between the United States and China, and growing U.S. protectionism are major headwinds that have been raising volatility in the semiconductor market.These pose a challenge to the upcoming quarterly results.

What Our Model Says

According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

STMicroelectronics currently has a Zacks Rank #3 and an Earnings ESP of 0.00%, making surprise prediction difficult.

Stocks That Warrant a Look

Here are a couple of stocks that you may want to consider, as our model shows that these have the right combination of elements to post a positive earnings surprise in the quarter to be reported.

Amazon.com, Inc. (NASDAQ:AMZN) has an Earnings ESP of +15.56% and carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Facebook, Inc. (NASDAQ:FB) has an Earnings ESP of +0.61% and a Zacks Rank #2.

Thermo Fisher Scientific Inc. (NYSE:TMO) has an Earnings ESP of +0.54% and holds a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Facebook, Inc. (FB): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

STMicroelectronics N.V. (STM): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.